Marc Wilson
Director of Finance/CFO at CRINETICS PHARMACEUTICALS, INC.
Net worth: 5 M $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Scott Struthers | M | 62 | 16 years | |
Stephen Betz | M | 58 | 16 years | |
Alan Krasner | M | 60 | 6 years | |
Weston Nichols | M | 39 | 6 years | |
Dana Pizzuti | M | 68 | 2 years | |
Stephanie Okey | F | 64 | 5 years | |
Wendell Wierenga | M | 76 | 9 years | |
Taylor Sandison | M | 52 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 11 years |
Rogério Vivaldi Coelho | M | 60 | 2 years | |
Caren Deardorf | F | 59 | 2 years | |
Camille Bedrosian | M | 71 | 4 years | |
Matthew Fust | M | 59 | 6 years | |
Jacqueline Pomfret Kirby | F | - | 1 years | |
Laura A. Navalta | F | - | 7 years | |
James Hassard | M | 57 | 2 years | |
Adriana Cabré | F | - | 4 years | |
Jeff Knight | M | 52 | 3 years | |
Matt McDowell | M | - | - | |
Brian Russell | M | - | 2 years | |
Michael Monahan | M | - | 6 years | |
Garlan Adams | F | - | 3 years | |
Allison Lewis | F | - | 9 years | |
Chris Robillard | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Matthew Onaitis | M | 53 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 3 years |
Nina Kjellson | F | 49 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 8 years |
Jeffrey Stein | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
John Schmid | M | 61 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 9 years |
J. Judice | M | 61 | 3 years | |
Steven Elms | M | 60 | 1 years | |
Michael Morneau | M | 58 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Mason W. Freeman | M | 73 | 4 years | |
Timothy Franson | M | 72 | 9 years | |
Paul Daruwala | M | 55 | 8 years | |
Jack Nielsen | M | 60 | 2 years | |
Theodore Schroeder | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 4 years |
Stephen W. Kaldor | M | 62 | 6 years | |
Risa Stack | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Patrick Heron | M | 53 | 1 years | |
Brendan M. O'Leary | M | 52 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 3 years |
Michael Powell | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Brian Atwood | M | 71 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
Karin Eastham | F | 74 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
Robert Perez | M | 59 | 3 years | |
Paul Truex | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Neil Abdollahian | M | 51 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 11 years |
Brady Johnson | M | - | 7 years | |
Gina Ford | M | - | 2 years | |
Jennifer Ellis | F | - |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 4 years |
Ajay Madan | M | 56 | 6 years | |
Michael Tomsicek | M | 58 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Robert Flath | M | - | - | |
David Kabakoff | M | 76 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 7 years |
John Thompson | M | 57 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Karen Potts | M | 61 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 4 years |
Kenneth Bartizal | M | 72 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 7 years |
Dirk Thye | M | 54 | 2 years | |
Mahendra Shah | M | 79 | 3 years | |
Seth Fischer | M | 68 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Thomas DesRosier | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Michael Bonney | M | 65 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Daniel Geffken | M | 67 | 4 years | |
David Hinkle | M | - | 3 years | |
Brendan Hannah | M | 39 | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 63 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marc Wilson
- Personal Network